ArticleBMC microbiology2025
A Tequintavirus bacteriophage SIA3lw isolated from sewage water with antimicrobial potential against antibiotic-resistant Salmonella Infantis.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSalmonella enterica serovar Infantis has consistently contributed to foodborne illness in recent years. Due to frequent antibiotic resistance challenges amid Salmonella species, promising antimicrobial alternatives, such as lytic bacteriophages, are considered to improve the efficacy of the antimicrobial interventions currently used in the food industry. Thus, this study aimed to characterize a new phage from sewage water for its antimicrobial potential against antibiotic-resistant S. Infantis. METHODS AND
resultsSalmonella phage vB_SalS-SIA3lw (or SIA3lw) was isolated from sewage water and subjected to genomic and biological characterization. In vitro antimicrobial activity of SIA3lw was determined against two antibiotic-resistant S. Infantis strains. Later, the antibiotic resistance profile of bacteriophage-insensitive mutants (BIMs) was also obtained. The phage has a long, non-contractile tail with a genome size of 116,541 bp and is genomically classified in the Tequintavirus genus, sharing a close evolutionary relationship with Escherichia phage Bf23. However, SIA3lw shared low nucleotide sequence similarities of receptor binding protein (ORF 22) and putative tail fiber protein (ORF 42) genes—both associated with bacterial host recognition and binding—with that in the Bf23. No genes associated with virulence, antibiotic resistance, and lysogeny were found. For biological traits, SIA3lw has a latent period of 30 min and an estimated burst size of 150 PFU/CFU against S. Infantis ATCC BAA-1675. The phage is polyvalent against various S. Infantis and two generic E. coli strains. Among different multiplicity of infections (MOIs), MOI = 100 was the most effective in reducing antibiotic-resistant S. Infantis strains in vitro by more than 4.5 log in 8 h at 25 °C. Despite the occurrence of BIMs, some became sensitive to streptomycin at certain dosages, to which wild-type Salmonella strains were resistant. Most importantly, all selected BIMs were susceptible to the infection by a T4-like phage.
conclusionsPhage SIA3lw has a large burst size and shows strong antimicrobial activities against antibiotic-resistant S. Infantis strains. Although BIMs occur after phage treatment, all BIMs are sensitive to a different phage infection. Most of all, some BIMs trade off their resistance to streptomycin at certain dosages for the development of phage resistance. These findings indicate that the newly isolated Tequintavirus phage SIA3lw has the antimicrobial potential to mitigate antibiotic-resistant Salmonella Infantis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.